Scarica l'app Stockscreener
8.875
2.81%
0.025
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché RNAZ Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.90
Aprire:
$8.9
Volume 24 ore:
653
Relative Volume:
0.00
Capitalizzazione di mercato:
$7.84M
Reddito:
-
Utile/perdita netta:
$-27.13M
Rapporto P/E:
-0.0367
EPS:
-242.0756
Flusso di cassa netto:
$-14.52M
1 W Prestazione:
+9.45%
1M Prestazione:
-6.49%
6M Prestazione:
-38.38%
1 anno Prestazione:
-17.89%
Intervallo 1D:
$8.5455
$8.90
Intervallo di 1 settimana:
$7.88
$10.30
Portata 52W:
$6.0829
$22.03
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Nome
Transcode Therapeutics Inc
Settore
Industria
Telefono
857-301-6857
Indirizzo
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
8.5455 | 8.16M | 0 | -27.13M | -14.52M | -242.08 |
VRTX
Vertex Pharmaceuticals Inc
|
439.36 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.21 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
838.50 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
332.17 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.80 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie
Aug Weekly: Is TransCode Therapeutics Inc showing insider buying2026 Major Catalysts & Daily Risk Controlled Trade Plans - baoquankhu1.vn
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
Geopolitics Watch: Can TransCode Therapeutics Inc sustain its profitability - baoquankhu1.vn
TransCode Therapeutics signs financing deal worth up to $20 million - MSN
Chipmakers Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averaging2026 Macro Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Big Picture: What is TransCode Therapeutics Incs P E ratio telling us2026 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
Insider Sell: Why is TransCode Therapeutics Inc stock going downEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
TransCode Therapeutics Secures New Financing to Extend Runway - The Globe and Mail
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 - Bitget
TransCode Therapeutics Secures Up to $20 Million Financing for Metastatic Cancer Trial - citybuzz -
TransCode Therapeutics Secures Up to $20 Million Flexible Financing to Advance Lead Cancer Program and Extend Runway Into 2028 - Minichart
Eightco (NASDAQ: ORBS) Represents the Biggest Public Market Exposure to OpenAI for Retail Investors - Weekly Voice
TransCode Therapeutics Secures $20M Financing - citybiz
Transcode Therapeutics Secures Up To $14 Million Standby Equity Facility and $6 Million Notes With Yorkville - TradingView — Track All Markets
TransCode Therapeutics (NASDAQ: RNAZ) lines up up to $20M in new flexible funding - Stock Titan
TransCode lands $20M to keep its cancer trial funded into 2027 - Stock Titan
Market Overview: How sensitive is TransCode Therapeutics Inc to inflationWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Form 8-KCurrent report - ADVFN
Responsive Playbooks and the RNAZ Inflection - Stock Traders Daily
RNAZ PE Ratio & Valuation, Is RNAZ Overvalued - Intellectia AI
TransCode Therapeutics, Inc. (RNAZ) Competitors - Meyka
TransCode Therapeutics Delays 2025 Annual Filing - The Globe and Mail
Bank Watch: Is TransCode Therapeutics Inc attractive for institutional investorsTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is TransCode Therapeutics Inc attractive for institutional investorsWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
RNAZ (RNAZ) delays 2025 Form 10-K after $25M preferred placement and acquisition - Stock Titan
Growth Value: Is TransCode Therapeutics Inc showing insider buying2026 Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Gap Down: Is TransCode Therapeutics Inc subject to activist investor interestAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Volume: What are analysts price targets for TransCode Therapeutics IncDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
Aug Mood: Does TransCode Therapeutics Inc have pricing power2026 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Bond Watch: Whats the outlook for TransCode Therapeutics Incs sector2026 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Understanding the Setup: (RNAZ) and Scalable Risk - Stock Traders Daily
Portfolio Update: Will TransCode Therapeutics Inc benefit from sector rotation2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
Is TransCode Therapeutics Inc undervalued by DCF analysis2026 Spike Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Breakout Zone: Should I hold or sell TransCode Therapeutics Inc now2026 Trends & Smart Money Movement Tracker - baoquankhu1.vn
Aug Chart Watch: Is TransCode Therapeutics Inc showing insider buyingWeekly Profit Summary & Momentum Based Trading Ideas - baoquankhu1.vn
The Technical Signals Behind (RNAZ) That Institutions Follow - Stock Traders Daily
RNAZ Should I Buy - Intellectia AI
How interest rate cuts could boost TransCode Therapeutics Inc. stockWeekly Profit Analysis & Safe Swing Trade Setup Alerts - Naître et grandir
Bank Watch: Is TransCode Therapeutics Inc a good ESG investmentJuly 2025 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
Aug Macro: Can TransCode Therapeutics Inc disrupt its industryJuly 2025 Chart Watch & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Weekly: Is TransCode Therapeutics Inc a speculative investmentTrend Reversal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Revista ADVFN
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits
TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal - The Globe and Mail
TransCode Therapeutics (NASDAQ: RNAZ) adds Unleash oncolytic platform in all-stock licensing deal - Stock Titan
TransCode licenses bladder cancer therapy platform from Unleash - Investing.com
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics Incenters exclusive license agreement with Unleash - marketscreener.com
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire
RNAZTransCode Therapeutics Announces Strategic Expansion of its Product Portfolio - mx.advfn.com
RNAZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Transcode Therapeutics Inc Azioni (RNAZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):